Protagonist Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals

On track to achieve 250 patient enrollment target in march 2024 top-line data for 32-week primary endpoint expected in the first quarter of 2025 newark, ca / accesswire / march 26, 2024 / protagonist therapeutics, inc. ("protagonist" or the "company") announced it has randomized 241 patients in the ongoing phase 3 verify clinical trial evaluating rusfertide in polycythemia vera ("pv") as of today and expects to meet the trial's 250 patient enrollment target by the end of march 2024. eligible patients in screening as of march 31, 2024 will be randomized by the end of april 2024.

Newark, ca / accesswire / march 18, 2024 / protagonist therapeutics, inc. ("protagonist" or the "company") today announces the closing of the worldwide collaboration and license agreement for rusfertide with takeda, a leading values-based, r&d-driven biopharmaceutical company, disclosed on january 31, 2024. closing of the transaction was contingent on completion of review under the hart-scott-rodino (hsr) antitrust improvements act of 1976 in the united states.

Newark, ca / accesswire / march 6, 2024 / protagonist therapeutics, inc. ("protagonist" or the "company") today announced that they will participate in three upcoming investor conferences: event: 2024 jefferies biotech on the bay summit date: march 12-13, 2024location: w hotel south beach, miami, fl. event: 13th annual napa valley biotech forum date: march 26-28, 2024presentation: tuesday, march 26 at 10:30-11:10 a.m.

Worldwide collaboration agreement executed with takeda pharmaceuticals, including a $300 million upfront payment for rusfertide in polycythemia vera and other hematological indications cash runway extended through q4 2027[1] two articles published in the new england journal of medicine reporting results from the phase 2b frontier 1 study of jnj-2113 and the phase 2 revive study of rusfertide our partner, johnson & johnson innovative medicine (formerly janssen) initiated an expanded jnj-2113 clinical development program with four phase 3 studies in moderate-to-severe psoriasis and one phase 2b study in moderately-to-severely active ulcerative colitis protagonist achieved $60 million in milestones in q4 related to jnj-2113 newark, ca / accesswire / february 27, 2024 / protagonist therapeutics (nasdaq:ptgx) ("protagonist" or "the company") today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided a corporate update...

- trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45% without phlebotomy - rusfertide was associated with lower disease-related symptoms in patients with moderate/severe scores at baseline as assessed by the myeloproliferative neoplasm symptom assessment form - revive is one of two pivotal studies, including an ongoing phase 3 study, verify, which is nearing enrollment completion newark, ca / accesswire / february 21, 2024 / protagonist therapeutics, inc. (nasdaq:ptgx) ("protagonist" or the "company") today announced publication in the new england journal of medicine (nejm) of the revive phase 2 study (nct04057040) results evaluating the efficacy and safety of rusfertide in polycythemia vera (pv), a myeloproliferative neoplasm affecting approximately 160,000 patients in the united states (us)...

Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The consensus price target hints at a 48.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Invest in stocks such as Protagonist Therapeutics (PTGX), Evolus (EOLS), Western Digital (WDC), and Phunware (PHUN) as of now for superb earnings acceleration.

NEWARK, CA / ACCESSWIRE / March 6, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that they will participate in three upcoming investor conferences: Event: 2024 Jefferies Biotech on the Bay Summit Date: March 12-13, 2024Location: W Hotel South Beach, Miami, FL. Event: 13th Annual Napa Valley Biotech Forum Date: March 26-28, 2024Presentation: Tuesday, March 26 at 10:30-11:10 A.M.

Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN), Western Digital (WDC) and Phunware (PHUN).

Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Does Protagonist Therapeutics (PTGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The average of price targets set by Wall Street analysts indicates a potential upside of 37.2% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Protagonist Therapeutics (PTGX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.